Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volanesorsen in Familial Partial Lipodystrophy with Hypertriglyceridemia and Uncontrolled Diabetes
2015-000493-35Phase 3Terminated
- Sponsor
- Akcea Therapeutics, Inc.
- Start
- Aug 2015
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in familial partial lipodystrophy (FPLD), hypertriglyceridemia and type 2 diabetes mellitus (T2DM) comparing Volanesorsen 300 mg weekly with Placebo then open-label volanesorsen (2 arms). Primary endpoint: Change in fasting triglycerides. Started Aug 2015; status: terminated.
02
Drugs
volanesorsen
03
Conditions
familial partial lipodystrophy (FPLD)hypertriglyceridemiatype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-000493-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000493-35.